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Smad4 functions as a transcription factor in TGF-b
signalling. We have investigated the role of Smad4 in the
TGF-b1 cell responses of transformed PDV keratino-
cytes, which contain a Ras oncogene, and of non-
tumorigenic MCA3D keratinocytes, by transfecting both
cell lines with a dominant-negative Smad4 construct.
Smad4 mediates TGF-b1-induced up-regulation of p21Cip1
and growth arrest in MCA3D cells. However, in PDV
keratinocytes, Smad4 is only partially involved in TGF-
b1-induced growth inhibition, and does not mediate
enhancement of p21Cip1 levels by the growth factor.
TGF-b1 activates Ras/Erk signalling activity in both cell
lines. PD098059, a specific inhibitor of MEK, dis-
minishes TGF-b1-induced p21Cip1 levels in PDV but not in
MCA3D cells, suggesting an involvement of Erk in up-
regulation of p21Cip1 by TGF-b1 in PDV cells. PDV
dominant-negative Smad4 cell transfectants, but not
MCA3D transfectants, showed constitutive hyperactiva-
tion of the Ras/Erk signalling pathway, increased
secretion of urokinase, higher motility properties, and a
change to a fibroblastoid cell morphology associated in
vivo with the transition from a well dierentiated to a
poorly dierentiated tumour phenotype. Infection of
MCA3D control and dominant negative Smad4 cell
transfectants with retroviruses carrying a Ras oncogene
led to enhanced p21Cip1 and urokinase secreted levels,
independently of TGF-b1 stimulation, that were reduced
by PD098059. These results suggest that Smad4 acts
inhibiting Ras-dependent Erk signalling activity in Ras-
transformed keratinocytes. Loss of Smad4 function in
these cells results in hyperactivation of Erk signalling
and progression to undierentiated carcinomas. Onco-
gene (2000) 19, 4134 – 4145.
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Introduction
Transforming growth factor-b (TGF-b) regulates cell
proliferation, dierentiation, motility, adhesion, and
death in most tissues, including epithelia (Massague´,
1990; Lahio and Keski-Oja, 1992). During the last
years the idea of a dual function of TGF-b in epithelial
carcinogenesis has gained considerable support. TGF-b
acts as a suppressor of tumour formation by virtue of
its role in inhibiting proliferation of epithelial cells
(Alexandrow and Moses, 1995; Massague´, 1998), but it
also stimulates malignant progression at later stages of
tumorigenesis by inducing an epithelial-mesenchymal
transition associated with the development of a highly
aggressive undierentiated type of tumour (Caulı´n et
al., 1995; Cui et al., 1996; Oft et al., 1996, 1998;
Frontelo et al., 1998; Portella et al., 1998).
Studies on the mouse skin carcinogenesis model and
on mammary epithelial cells suggest a synergistic co-
operation between oncogenic Ras and TGF-b1 to
stimulate malignant progression (Oft et al., 1996;
Akhurst and Balmain, 1999). The eects of the growth
factor on carcinoma cell invasiveness and metastasis
appear to be direct and require signalling through the
type II receptor (Oft et al., 1998; Portella et al., 1998).
TGF-b signals through formation of heteromeric
complexes between type I and type II serine/threonine
kinase receptors. After activation, the signal transdu-
cing type I receptor binds and phosphorylates Smad2/
Smad3 proteins that associate with Smad4 in the
cytoplasm, and these complexes, then, translocate into
the nucleus in which they activate transcription of
specific genes (see Massague´, 1998; Zhang and
Derynck, 1999; for reviews). TGF-b signalling compo-
nents, such as type II receptors and Smad proteins,
have been shown to be inactivated by mutation or
deletion in human cancers (Massague´, 1998). Particu-
larly, Smad4 (DPC4) was originally identified as a
tumour suppressor gene frequently inactivated in
pancreatic and colon carcinomas. Reconstitution of
Smad4 in colon carcinoma defective cells leads to
suppression of tumorigenicity (Schwarte-Waldho et
al., 1999)
Several reports point to a rapid and direct activation
of the Ras-mitogen-activated protein (MAP) kinase
signalling pathway associated with growth inhibition
by TGF-b in epithelial cells (Hartsough et al., 1996;
reviewed in Hartsough and Mulder, 1997). The growth
inhibitory response to TGF-b appears to be mediated
by induction of cyclin-dependent kinase (cdk) inhibi-
tors, such as p21Cip1 and p15INK4B (Datto et al., 1995;
Hannon and Beach, 1994; Reynisdo´ttir et al., 1995).
The signalling pathways involved in these TGF-b-
induced gene responses remain an open question (see
Massague´, 1998). Thus, p21Cip1 appears to be a
downstream target gene regulated by Smad4 in
carcinoma cells (Grau et al., 1997; Hunt et al., 1998),
while it has been reported that Ras and the MAP
kinase pathway are required for up-regulation of
p21Cip1 by TGF-b in intestinal epithelial cells and
human keratinocytes, respectively (Yue et al., 1998; Hu
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et al., 1999). The same appears to occur for TGF-b-
mediated induction of other genes, such as the 3TP-lux
reporter construct, which contains a known TGF-b-
inducible plasminogen activator inhibitor-1 (PAI-1)
promoter (Grau et al., 1997; Mucsi et al., 1996; de
Winter et al., 1997). This scenario has been compli-
cated as several reports demonstrate a cross-talk
between the Smad and Ras-MAP kinase signalling
pathways (reviewed in Zhang and Derynck, 1999).
Recently, Kretzschmar et al. (1999) found that
oncogenic Ras, acting via MAP kinases, inhibits
TGF-b-induced nuclear accumulation of Smad2 and
Smad3. However, another report has shown that
constitutively active MEK, or inhibitors for MEK,
have no eect on Smad activity in human keratinocytes
(Hu et al., 1999).
In this work, we have analysed the role of Smad4 in
the TGF-b1 responses of immortalized (MCA3D) and
transformed (PDV) mouse epidermal keratinocytes by
transfecting both cell lines with a C-terminal truncated,
dominant-negative, Smad4 construct (Lagna et al.,
1996). MCA3D cells are non-tumorigenic and exhibit
normal Ras and p53 genes, while PDV are chemically
transformed keratinocytes and produce low metastatic
well dierentiated squamous cell carcinomas upon
injection in mice (Caulı´n et al., 1995; Frontelo et al.,
1998). PDV cells contain a mutated H-Ras gene and
express relatively low levels of activated Ras proteins
(Quintanilla et al., 1991). They also have inactivated
p53 loci (Burns et al., 1991). Both cell lines are growth-
inhibited by TGF-b1, but they respond dierentially to
chronic treatment with the growth factor. While
MCA3D cells are induced to terminal dierentiation
and cell death in response to TGF-b1, the growth
factor stimulates cell motility and invasiveness in PDV
cells, which undergo a reversible epithelial-mesenchy-
mal conversion linked to progression toward a
metastatic poorly dierentiated tumour phenotype
(Caulı´n et al., 1995; Frontelo et al., 1998). The invasive
response of PDV and other carcinoma cells to TGF-b1
is associated with enhanced expression/secretion of
urokinase (uPA) and of its inhibitor PAI-1 (Farina et
al., 1998; Santiba´n˜ez et al., 1999). uPA is a serine
proteinase that converts the inactive plasminogen into
the broad-spectrum active proteinase plasmin, which in
turn degrades many proteins of the extracellular matrix
and activates other matrix metalloproteinases (Andrea-
sen et al., 1997).
We show that inhibiting Smad4 in Ras-transformed
keratinocytes leads to hyperactivation of the Ras/Erk
signalling pathway, increased secretion of uPA, and
progression to a poorly dierentiated tumour pheno-
type. On the other hand, a switch between the Smad
and Erk signalling pathways, depending on the
presence of oncogenic Ras, appears to occur in
keratinocytes to mediate induction of p21Cipl by TGF-
b1.
Results
Smad4 mediates growth inhibition in both MCA3D and
PDV keratinocytes
MCA3D and PDV cell lines were transfected either
with a full-length Smad4 cDNA or with a C-terminal
truncated dominant-negative Smad4 (1 – 514) construct,
together with the pcDNA3 neomycine resistant vector.
Previously, the presence of Smad4 transcripts in both
cell lines was demonstrated by RT –PCR (data not
shown). After transfection with the normal full-length
cDNA, no viable clones were obtained from MCA3D
cells; while several clones could be selected up to the
third passage, in which they died, in the case of PDV
cells. These results suggest that overexpression of
Smad4 induces cell death in keratinocytes, as reported
for other epithelial cells (Atfi et al., 1997), although
this hypothesis was not further investigated. Stable
clones transfected with the dominant-negative Smad4
(1 – 514) construct were isolated from both MCA3D
and PDV cell lines (designated as 3DdnS and PdnS,
respectively). Clones transfected with the pcDNA3
vector alone were also obtained (designated as 3DC
and PC) to be used as controls.
The activity of Smad signalling in the transfectants
was analysed by measuring TGF-b1-induced nuclear
accumulation of Smad2/Smad3 in immunofluorescence
experiments using a specific anti-Smad2,3 antibody
(Figure 1). In exponentially growing MCA3D and
PDV cells, untreated with TGF-b1, anti-Smad2,3
staining was predominantly cytoplasmic concentrated
at the perinuclear region, although about 18% of the
cells showed Smad2/Smad3 accumulated in the nucleus
(Figure 1a,b). This percentage of unstimulated cells
with Smad2,3 localized into the nucleus was probably
as consequence of TGF-b factors present in the serum
or secreted by their own cells. In any case, on addition
of TGF-b1, about 90% of MCA3D cells showed anti-
Smad2,3 staining concentrated into the nucleus. This
response was rapid, with a maximum at 20 min, and
lasted for about 1 h (Figure 1b). PDV cells responded
partially to TGF-b1-induced nuclear translocation of
Smad2,3. Anti-Smad2,3 nuclear staining was limited to
about 40% of the cells at 30 min of treatment (Figure
1a,b), indicating a constitutive inhibition of Smad
signalling in these transformed keratinocytes, likely
because of the presence of a Ras oncogene (Kretzsch-
mar et al., 1999). 3DdnS and PdnS transfectants did
not respond to TGF-b1 for nuclear accumulation of
Smad2,3 (see in Figure 1c the results obtained with
3DdnS18, PdnS7 and PdnS8; other clones, such as
3DdnS16, 3DdnS17 and PdnS5, behaved similarly),
while nuclear translocation of Smad proteins was
stimulated in control clones as in the corresponding
parental cell lines (not shown). These results clearly
indicated that the Smad transduction pathway was
blocked in the dominant-negative Smad4 transfectants.
Although MCA3D cells are most sensitive than PDV
for TGF-b1-induced growth inhibition, both cell lines
are growth-inhibited by concentrations of TGF-b1
above 1 ng/ml (Haddow et al., 1991). As shown in
Figure 2, TGF-b1, at 10 ng/ml, inhibited the growth of
3DC and PC control cell clones after 48 h of
treatment. All of the dominant-negative Smad4
transfectant clones showed resistance to growth
inhibition, but, while it was drastically reduced in
3DdnS cells (Figure 2a), a significant inhibition of
growth was still induced by TGF-b1 in PdnS clones
(Figure 2b), suggesting that other signalling pathways,
in addition to Smad, could be involved in the
antiproliferative response of transformed keratinocytes
to TGF-b1.
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We also analysed the activation by TGF-b1 of 3TP-
lux, a TGF-b-inducible reporter gene containing a
PAI-1 promoter. Previous results indicated that TGF-
b1 induced a twofold activation of 3TP-lux in PDV
cells after 24 h of treatment, while MCA3D cells were
unable to respond to the growth factor for PAI-1
induction (Santiba´n˜ez et al., 1999). As shown in Figure
2c, TGF-b1 activated 3TP-lux in the control PC2 clone
(about twofold), while no significant activation of the
reporter gene was found in PdnS transfectants. This
result indicates that Smad4 is a key element in the
TGF-b signal transduction cascade in transformed
keratinocytes.
Smad4 mediates up-regulation of p21Clp1 by TGF-b1 in
MCA3D, but not in PDV cells in which the Erk signalling
pathway is required
It has been demonstrated that TGF-b1 induces the
expression of the cdk inhibitor p21Cip1 in normal and
transformed keratinocytes, and that induction of
p21Cip1, together with alterations in other cell cycle
regulatory molecules, seems to be partially respon-
sible of the growth-inhibitory eects of TGF-b1
(Malliri et al., 1996). We studied the expression of
p21Cip1 in control and dominant-negative Smad4 cell
transfectants by Western blot analysis of cell extracts
obtained from synchronous exponentially growing
cultures, untreated or treated with TGF-b1 (Figure
3). No significant dierences for induction of p21Cip1
in response to TGF-b1 were observed when cells were
cultured in the presence or absence of serum,
although the basal protein levels of p21Cip1 (relative
to the expression of b-actin, used as a protein
loading marker) were higher when serum was present.
Exposure to TGF-b1 resulted in a fivefold induction
of p21Cip1 protein expression in 3DC and PC control
clones (Figure 3a – c). This response was blocked in
3DdnS transfectants (Figure 3a), while no dierences
for TGF-b1 up-regulation of p21Cip1 were observed
between control PC and dominant-negative PdnS
transfectants (Figure 3b,c). Since the Erk MAP
kinase signalling pathway has also been implicated
in the regulation of p21Cip1 by TGF-b in epithelial
cells (Yue et al., 1998; Hu et al., 1999), we studied
the eects of PD098059, a specific inhibitor of MAP
kinase kinase (MEK) (Simon et al., 1996), on p21Cip1
protein induction by TGF-b1. PD098059, at a
concentration of 50 mM (that is shown to inhibit
eciently Erk signalling activity in PDV cells, see
Figure 1 TGF-b1-induced nuclear accumulation of Smad2/Smad3 in MCA3D and PDV cells, and in dominant-negative Smad4
transfectants. (a) Endogenous Smad2 and Smad3 were visualized by anti-Smad2,3 immunofluorescence staining in MCA3D and
PDV cells untreated or treated with TGF-b1 for 20 min and 30 min, respectively. (b) MCA3D and PDV cells were treated with
TGF-b1 for dierent time periods. Following immunofluorescence staining, the percentage of cells with Smad2,3 staining
concentrated in the nucleus was calculated as described in Materials and methods. (c) Nuclear accumulation of Smad2,3 in response
to TGF-b1 in MCA3D, PDV and dominant-negative Smad4 transfectants. Treatments with the growth factor were of 20 min for
MCA3D and 3DdnS18, and of 30 min for PDV, PdnS7 and PdnS5
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below), consistently reduced (by 35 – 50%) TGF-b1-
stimulated p21Cip1 expression in PC and PdnS clones,
while it did not aect the enhancement of p21Cip1 by
the growth factor in 3DC cells (Figure 3c).
Altogether, these data indicated that Smad4 does
not mediate regulation of p21Cip1 protein levels by
TGF-b1 in transformed PDV keratinocytes, and that
this response appeared to require Erk MAP kinase
signalling activity.
To study whether the expression of oncogenic Ras
could explain the involvement of Erk in the modula-
tion of p21Cip1 levels by TGF-b1 in PDV cells, we
infected 3DC and 3DdnS transfectants with retro-
viruses carrying an activated H-Ras gene, and
analysed the levels of p21Cip1 in the absence and
presence of TGF-b1. Infection of the cells with the
Harvey murine sarcoma virus (HMSV) produced a
relatively high level of oncogenic Ras protein expres-
sion (see below), and resulted in a strong basal
induction (4 – 7-fold) of p21Cip1 protein levels (Figure
3d,e). This increase was similar to that induced by
TGF-b1 in non-infected 3DC cells (Figure 3d), and
occurred in both control and dominant-negative
Smad4 transfectants. p21Cip1 protein levels in Ras-
infected cells were significantly reduced by treatment
with PD098059 (Figure 3e).
TGF-b1 induces a rapid and transient activation of Ras
and Erk in MCA3D and PDV keratinocytes
Therefore, we studied whether TGF-b1 was able to
activate the Ras/Erk signalling pathway in MCA3D
and PDV keratinocytes. Ras signalling activity was
analysed by measuring the levels of Ras-GTP in
unstimulated and TGF-b1-stimulated cells (Figure 4).
As expected, the basal level of active Ras-GTP was
strikingly higher in PDV compared to MCA3D cells.
TGF-b1 induced a rapid and transient enhancement of
Ras-GTP levels in both cell lines, without changing
Ras protein expression. Maximal activation for both
cell lines occurred at 2 min of treatment, and a decay
to baseline levels at about 10 min (Figure 4a,b).
We also studied the activity of Erk by analysing the
immunofluorescent localization of Erk proteins using
an antibody that recognizes both Erk1 and Erk2
isoforms. Activation of Erk occurs in the cytoplasm
and implies phosphorylation by MEK and transloca-
tion into the nucleus (Davis, 1993; Hill and Treisman,
1995). As shown in Figure 5a,b, Erk proteins were
found mostly in the cytoplasm of unstimulated
MCA3D and PDV cells, and only a small percentage
of the cell population (below 5% in MCA3D and
about 12% in PDV) exhibited Erk nuclear localization.
Figure 2 TGF-b1-induced growth inhibition and transcriptional activation of the 3TP-lux reporter in the cell transfectants. (a, b)
Cell growth inhibition assays in control (3DC, PC) and dominant-negative Smad4 (3DdnS, PdnS) transfectants. Synchronized cells,
about 16106 cells in (a) and 4.56105 cells in (b), were seeded in 20-cm2 culture dishes and grown in medium plus serum. TGF-b1
treatment started on the following day. After 48 h, cells on TGF-b1-treated (diagonally stripped bars) and untreated (black bars)
dishes were counted. The figures represent the means (+s.d.) of quadruplicate incubations. (c) Induction of 3TP-lux by TGF-b1 in
PDV cell transfectants. Cells were transiently transfected with the 3TP-lux reporter plasmid and incubated without or with TGF-b1
for 24 h. Luciferase activity in the cell lysates, corrected for transfection eciency as indicated in Materials and methods, was
plotted as the average (and s.d.) for duplicate determinations of two independent experiments
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The higher percentage of Erk nuclear accumulation in
PDV cells indicated a certain constitutive activation of
Erk signalling in basal conditions, consistent with the
presence of elevated levels of Ras-GTP in this latter
cell line. On TGF-b1 addition, Erk proteins were
transiently translocated into the nucleus in about 90%
of both MCA3D and PDV cells, although with a slight
dierence in their kinetic profiles: Maximal nuclear
accumulation occurred at 15 – 30 min (PDV) and 30 –
60 min (MCA3D), and the final slope of the kinetics
was more pronounced in MCA3D cells (Figure 5a).
The eect of the MEK inhibitor PD098059 on TGF-
b1-induced nuclear translocation of Erk was analysed
in PDV cells. Treatment of the cells with increasing
concentrations of PD098059 resulted in a dose-
dependent inhibition of Erk nuclear accumulation
(Figure 5c). Inhibition was none at 10 mM, partial at
25 mM, and complete at 50 mM. TGF-b1 stimulated the
levels of phosphorylated Erk proteins, as shown in the
Western blot of Figure 5d, in which a specific
monoclonal antibody that recognizes the phosphory-
lated forms of both Erk1 and Erk2 was used. Increased
phosphorylation of Erk was more evident in Erk2, did
not involve changes in Erk protein expression, and was
inhibited by PD098059 at 50 mM (Figure 5d).
Blockade of Smad4 in transformed keratinocytes leads to
hyperactivation of the Ras/Erk signalling pathway
associated with increased secretion of urokinase and
tumour progression
Thereafter, we analysed the nuclear localization of Erk
proteins in the transfectants before and after a
treatment of 30 min with TGF-b1. Untreated PdnS
clones consistently showed increased basal nuclear
localization of Erk proteins (about 40% of the cells)
respect to PC controls (about 10%); suggesting that the
level of Erk signalling is further increased in PDV
dominant-negative Smad4 cells. In contrast, the
percentage of cells with Erk accumulated in the nucleus
was similar (2 – 3%) in untreated 3DC and 3DdnS cells
(Figure 6b), indicating that inhibition of Smad4 in
non-transformed keratinocytes had no eect on the
Erk pathway. TGF-b1 stimulated nuclear translocation
Figure 3 Induction of p21Cip1 protein expression by TGF-b1 in MCA3D and PDV cell transfectants. Eect of PD098059 on TGF-
b1-stimulated p21
Cip1 levels. (a, b) Lysates from synchronized cells grown in complete medium, untreated or treated with TGF-b1 for
the indicated time periods, were subjected to Western immunoblotting with an anti-p21Cip1 monoclonal antibody. The level of b-
actin expression, as a protein loading control, was also determined. (c) p21Cip1 protein expression was determined in lysates from
cells grown in medium minus serum, unstimulated or stimulated with TGF-b1 for 24 h, in the absence or presence of 50 mM
PD098059. The figure shows a representative experiment out of three. PD098059 inhibited induction of p21Cip1 by TGF-b1 in PC
and PdnS but not in 3DC2 cells. Similar results were obtained with the 3DC3 clone and with the parental cell line (not shown). (d,
e) Infection of MCA3D control and dominant-negative Smad4 cell transfectants with oncogenic Ras induces p21Cip1. (e) PD098059
inhibits Ras-induced p21Cip1 levels in 3DdnS18 cells. Similar results were obtained with 3DC-Ras clones (not shown). Stimulation
with TGF-b1 was in the absence (d) or presence (e) of serum. Quantitation of both p21
Cip1 and b-actin was performed by
densitometric analysis to correct for dierences in loading. Values indicated at the bottom of auto-radiographs are expressed relative
to untreated cells, in which an arbitrary value of 1 was given
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Figure 4 TGF-b1 activates Ras in MCA3D and PDV cells. (a) Cells were stimulated with TGF-b1 for dierent time periods (0 –
30 min). The levels of Ras-GTP were determined in the cell lysates (1.1 mg of total protein) by precipitating with RBD-Sepharose
followed by Western immunoblotting with a pan-Ras monoclonal antibody. The level of Ras protein expression was also
determined in the cell lysates. (b) Quantitation of the Ras-GTP levels of the experiment showed in (a) was performed by
densitometric analysis. A representative experiment out of three is presented
Figure 5 TGF-b1 activates Erk signalling in MCA3D and PDV cells. Eect of the MEK inhibitor PD098059. (a, b) TGF-b1-
induced nuclear accumulation of Erk proteins in MCA3D and PDV cells. (a) MCA3D and PDV cells were stimulated with TGF-b1
for dierent time periods (0 – 24 h) and Erk proteins localized by immunofluorescence analysis with a polyclonal antibody
recognizing Erk1 and Erk2 isoforms. The percentage of cells with Erk predominantly or exclusively in the nucleus was determined
as described in Materials and methods. (b) Immunolocalization of Erk proteins in unstimulated cells or cells stimulated with TGF-b1
for 30 min. (c) TGF-b1-induced nuclear accumulation of Erk1,2 in PDV cells is inhibited by PD098059. Unstimulated cells, or cells
stimulated with TGF-b1 for 30 min, were treated with dierent concentrations of PD098059, and the percentage of cells with Erk1,2
accumulated in the nucleus determined. Values represent the means (+s.d.) of counts from three independent experiments. (d) TGF-
b1 stimulates phosphorylation of Erk proteins in PDV cells. Eect of PD098059. Lysates from unstimulated cells, or from cells
stimulated with TGF-b1 for 30 min, untreated or treated with PD098059 at the indicated concentrations, were subjected to Western
immunoblotting with antibodies recognizing total Erk1,2 proteins (bottom) or their phosphorylated forms (p-Erk)
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of Erk at the same extent (90 – 100%) in all clones
(Figure 6a,b). In Ras-infected 3DC and 3DdnS cells,
nuclear accumulation of Erk raised maximum levels in
basal conditions, masking the eect of TGF-b1 (Figure
6b). As expected, low levels of phospho-Erk1,2
proteins were found in 3DC and 3DdnS cells.
Phosphorylation of both isoforms increased after
infection with Ras or stimulation with TGF-b1 (Figure
6c). In contrast, enhanced levels of phospho-Erk2, but
not of phospho-Erk1, were observed in unstimulated
PdnS transfectants compared with control PC4 cells
(Figure 6c). We also analysed the activity of Ras
signalling by comparing the levels of Ras-GTP in PC
and PdnS transfectants. PdnS7 and PdnS8 cells showed
elevated levels of Ras-GTP respect to control PC4
cells, and this enhancement was not due to increased
Ras protein expression (Figure 6d). The same result
was obtained with PdnS5 (not shown). These findings
are consistent with the idea that inhibition of Smad4 in
transformed PDV keratinocytes leads to a constitutive
hyperactivation of the Ras/Erk transduction pathway
mediated by phosphorylation of Erk2.
Treatment of PDV cells with TGF-b1 up-regulates
uPA expression/secretion associated with stimulation
of cell motility and invasiveness (Santiba´n˜ez et al.,
1999). We show in another report that stimulation of
uPA production by TGF-b1 in PDV cells requires the
Ras/Erk signalling pathway (Santiba´n˜ez et al., 2000).
Interestingly, PdnS clones consistently secreted in-
creased amounts of uPA compared with control clones
(Figure 7a) or the parental cell line (not shown).
Treatment with TGF-b1 for 24 h stimulated uPA
production about threefold in PC cells and slightly
enhanced the levels of uPA secreted by some PdnS
clones (Figure 7a,b). Both basal and TGF-b1-induced
levels of uPA secreted by PdnS cells were inhibited by
PD098059 at 50 mM, which also reduced uPA secretion
in TGF-b1-stimulated PC cells, as exemplified with
PdnS8 and PC4 clones in Figure 7b. Nevertheless,
dominant-negative 3DdnS cells did not increase basal
secretion of uPA respect to the parental cell line
(Figure 7c) or control clones (not shown). In
unstimulated MCA3D cells, secreted uPA was en-
hanced by overexpression of oncogenic Ras after
retroviral infection, and this increase was also inhibited
by PD098059 (Figure 7c). The same result was
obtained in 3DdnS cells (not shown).
To analyse whether enhanced secretion of uPA in
PdnS clones correlated with increased motility, we
performed an in vitro wound healing assay comparing
the abilities of PC and PdnS clones to repopulate a
wound made 24 h before (Figure 8a,b). PdnS clones
showed higher migratory abilities than PC in unstimu-
lated conditions. TGF-b1 enhanced cell motility of all
clones, although the eect was more pronounced in
control PC cells. To demonstrate the involvement of
Figure 6 Comparison of Erk and Ras activation in control and dominant negative Smad4 cell transfectants. (a) Nuclear
accumulation of Erk in PDV cell transfectants unstimulated (black bars) or stimulated with TGF-b1 (diagonally striped bars) for
30 min. (b) Nuclear accumulation of Erk in non-infected and Ras-infected MCA3D cell transfectants unstimulated or stimulated
with TGF-b1 as above. Ras-infected cells express relatively high levels of viral Ras proteins, which migrate with a slightly lower
mobility than endogenous normal Ras proteins in polyacrylamide gels, as shown by Western immunoblotting with a pan-Ras
monoclonal antibody (insert). (c) Erk phosphorylation levels in dierent cell lines. The relative levels of total and phosphorylated
Erk1 and Erk2 proteins were determined as in the legend to Figure 5d. (d) Comparison of Ras activation in PDV cell transfectants.
The levels of Ras bound to GTP and Ras protein expression were determined in the cell lysates (0.7 mg of total protein) as in the
legend of Figure 4
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uPA in the motility properties of the cells, we
synthesized a peptide (P41 – 54) comprising aminoacids
residues 41 – 54 of the amino-terminal domain of
mouse uPA. This fragment was shown to be a potent
antagonist of the binding of uPA to its high anity
cell-surface receptor (Min et al., 1996), and to inhibit
TGF-b1-stimulated cell motility and invasiveness of
PDV cells (Santiba´n˜ez et al., 1999). As shown in Figure
8a,b, treatment with P41 – 54 strongly reduced basal
cell motility of PdnS cells, and blocked migration
stimulated by TGF-b1 in PC and PdnS clones, while
unrelated control peptides had no eect (not shown).
Importantly, a clear change to a fibroblastoid cell
morphology was observed in PdnS clones respect to PC
or PDV keratinocytes (Figure 8c). 3DdnS transfec-
tants, on the other hand, exhibited morphological
appearances (Figure 8c) and low migratory abilities
(not shown) similar to that of the parental cell line. To
analyse the behaviour of PC and PdnS clones in vivo,
cells were transplanted into nude mice by i.d. injection
and their tumorigenic characteristics compared (Table
1). No significant changes in the rates of tumour
growth were observed between PC and PdnS clones,
although PC-induced tumours tend to appear earlier.
Notwithstanding, a striking dierence was observed in
the tumour phenotypes (Figure 9, Table 1). PC
tumours were histologically typed as well dierentiated
squamous cell carcinomas (see PC2 in Figure 9), and
only small areas moderately/poorly dierentiated were
observed in two PC4 tumours (not shown). In PdnS
tumours, keratinizing areas were absent (see PdnS8 in
Figure 9), or, when present in some tumour sections
(two PdnS7 and one PdnS5), representing less than
25% of the total tumour surface. Consequently, all
PdnS tumours were typed as poorly dierentiated
carcinomas.
Discussion
In this study we demonstrate that TGF-b1 activates
both the Ras/MAP kinase and Smad signalling path-
ways in keratinocytes. Smad signalling mediates TGF-
b1-induced growth arrest and up-regulation of p21Cip1
in non-transformed MCA3D keratinocytes, as 3DdnS
dominant-negative Smad4 cell transfectants exhibited a
block in these responses. In transformed PDV
keratinocytes, however, other pathways besides Smad
are implicated for TGF-b1-induced growth inhibition.
Modulation of p21Cip1 expression by TGF-b1 in PDV
cells is independent of Smad4 and requires Erk MAP
kinase signalling activity. Therefore, both the Smad
and MAP kinase pathways can be involved in the
regulation of p21Cip1 expression by TGF-b1 in kerati-
nocytes. A key factor for the dierent responses of
MCA3D and PDV cells appears to be the presence of
an activated Ras gene in the latter cells (Quintanilla et
al., 1991). Overexpression of oncogenic Ras in
MCA3D cells by retroviral infection induced a high
level of p21Cip1 protein regardless of blocking Smad4 or
not. These levels were comparable to that induced by
TGF-b1 in non-infected cells, and were inhibited by
PD098059. The high basal level of p21Cip1 observed in
Ras-infected MCA3D compared to PDV cells is likely
due to the higher oncogenic Ras dosage expressed by
3D-Ras cells. It has been demonstrated that, in certain
situations, activation of Ras induces p21Cip1 expression
and cell cycle arrest via the Erk MAP kinase
transduction pathway (reviewed in Lloyd, 1998).
Constitutively active Ras requires Rho signalling for
suppression of p21Cip1 induction (Olson et al., 1998).
This mechanism could be operating in PDV cells to
maintain low basal levels of p21Cip1. In support of this
hypothesis is the observation by Adnane et al. (1998)
that a dominant-negative mutant of RhoA activates
p21Cip1 expression, while constitutively active RhoA
repress it, in the pancreatic carcinoma cell line Panc-1,
which contain an activated K-Ras gene. The fact that
TGF-b1 is able to up-regulate p21Cip1 levels in PDV
(this study) as well as in Panc-1 cells (Grau et al., 1997)
might imply that the growth factor regulates negatively
Rho activity. Studies aimed to evaluate the involve-
ment of Rho GTPases in the PDV cell responses to
TGF-b1 are currently in progress.
Nevertheless, the most striking finding in this study
is that inactivation of Smad4 in transformed PDV
keratinocytes, but not in nontumorigenic MCA3D
cells, leads to increased activity of the Ras/Erk
signalling pathway; as found by enhanced levels of
Ras-GTP, phosphorylated Erk2, and nuclear accumu-
lation of Erk proteins, in dominant-negative PdnS
transfectants compared to PC control cells. These
observations suggest a new type of interaction by
Figure 7 uPA secreted activity is increased in PDV dominant-
negative Smad4 cell transfectants. (a) Zymographic analysis of
uPA activity determined in the conditioned serum-free media of
PDV cell transfectants unstimulated or stimulated with TGF-b1
for 24 h. (b) Eect of PD098059 (50 mM) on the basal and TGF-
b1-stimulated uPA levels secreted by PDV cell transfectants. (c)
uPA activity secreted by non-infected MCA3D and 3DdnS18
cells, and Ras-infected MCA3D cells, unstimulated or stimulated
with TGF-b1 for 24 h. Eect of PD098059. Since MCA3D cells
express/secrete 4 – 5-fold lower levels of uPA than PDV
(Santiba´n˜ez et al., 1999), aliquots of conditioned media used for
determinations of uPA were normalized for a protein concentra-
tion of 0.5 mg/ml in (a, b), and of 2.5 mg/ml in (c)
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which Smad4, directly or indirectly, inhibits Ras
signalling activity in transformed keratinocytes, in
addition to the mechanism of repression of Smad
signalling by oncogenic Ras/MAP kinases proposed by
Kretzschmar et al. (1999). However, the molecular
basis for this cross-talk between Smad4 and Ras
remains to be investigated.
The functional consequences of inactivating Smad4
in PDV cells are increased secretion of uPA, enhanced
motility, and a change toward a fibroblastoid cell
morphology associated with the development of poorly
dierentiated tumours. High levels of secreted uPA are
commonly associated with tumoural invasiveness and
metastasis and with a poor patient prognosis (Andrea-
sen et al., 1997). The finding that PD098059 reduces
uPA secretion in dominant-negative PdnS transfectants
to levels similar to that of unstimulated PDV
keratinocytes, suggest an involvement of the MAP
kinase cascade to regulate enhanced production of uPA
in PdnS cells, probably through hyperactivation of Ras
signalling activity. In fact, the Ras/MAP kinase
pathway is required for TGF-b1 to modulate uPA
expression/secretion in PDV cells (Santiba´n˜ez et al.,
2000).
Taken together, our results suggest that the presence
of an activated Ras gene and loss of Smad4 function
cooperates for malignant progression. This co-opera-
tion might be physiologically relevant in certain
tumours where oncogenic mutations in Ras coincides
with functional inactivation of Smad4, as occurs in
pancreatic and colon carcinomas. Pancreatic adeno-
carcinomas exhibit the highest rate of activating Ras
(K-Ras) mutations found in human tumours with a
frequency above 90% (Almoguera et al., 1988;
Rozenblum et al., 1997), and about 50% of carcinomas
have inactivated Smad4 (DPC4) (Hahn and Schmiegel,
Figure 8 PDV dominant-negative Smad4 cell transfectants exhibit enhanced migratory abilities and a change toward a
fibroblastoid cell morphology. (a) Wounds made in subconfluent cell cultures of PC2 and PdnS5 clones were examined after 24 h of
culturing in the absence or presence of TGF-b1. The uPA synthetic peptide P41-45, added at 150 mg/ml, inhibits both basal and
TGF-b1-stimulated cell motility. Bar, 50 mm. (b) Diagram showing quantitation of the cell motility assay made with dierent PDV
cell transfectants. Cells invading the wound were counted in three dierent fields as those showed in the micrographs. The figure
represents the mean values (+s.d.) of migrated cells in the dierent experimental conditions. (c) Phase contrast micrographs of
representative MCA3D (3DC2, 3DdnS18) and PDV (PC2, PdnS7) cell clones transfected with the neo vector alone or the dominant-
negative Smad4 construct. The rest of 3DdnS and PdnS clones exhibited similar morphological appearances as those of 3DdnS18
and PdnS7. Bar, 25 mm
Table 1 Tumorigenicity of the cell lines in nude mice
Tumours/ Latencya
Cell clone sites (weeks) Tumour histologyb
PC4 5/5 2.5 – 4 Well diff. SCC
PC2 6/6 2 – 3 Well diff. SCC
PdnS5 6/6 4 – 5 Poorly diff. SCC
PdnS7 5/5 4.5 – 5 Poorly diff. SCC
PdnS8 5/5 3 – 5 Poorly diff. SCC
aThe latency period was estimated as the time needed for tumours to
reach a size of 0.5-cm2. bSCC, squamous cell carcinoma
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1998; Rozenblum et al., 1997). These frequencies are
lower in colon carcinomas with approximately 50% of
the tumours containing mutations in K-Ras (Bos et al.,
1987; Burmer et al., 1990) and about 15% loss of
Smad4 (DPC4) (MacGrogan et al., 1997; Thiagalingam
et al., 1996). It would be of clinical interest to analyse
whether the combination of an oncogenic Ras
mutation (an early event in carcinogenesis) and
inactivated Smad4 suppressor genes (a late event) is a
prognostic factor for the development of more
malignant undierentiated carcinomas. In supporting
this possibility, a recent study in which more than 100
cell lines and primary tumours were analysed for MAP
kinase activity resulted in pancreas and colon tumour
cells exhibiting high frequencies of constitutive MAP
kinase activation that correlated with a poorly
dierentiated tumour phenotype (Hoshino et al.,
1999). On the other hand, another report has shown
that sustained activation of the MAP kinase cascade in
MDCK cells leads to an epithelial-fibroblastic conver-
sion associated with increased migratory and invasive
properties (Montesano et al., 1999).
Materials and methods
Cell culture, treatment conditions and transfection procedures
The origin and characteristics of MCA3D and PDV cell lines
have been described previously in several reports (Quintanilla
et al., 1991; Caulı´n et al., 1995; Santiba´n˜ez et al., 1999). Cells
were grown in Ham’s F-12 medium supplemented with amino
acids and vitamins (GIBCO, Ltd., Paisley, Scotland), 10%
foetal bovine serum, and antibiotics (2.5 mg/ml amphotericin
B, 100 mg/ml ampicillin, and 32 mg/ml gentamicin; Sigma
Chemical Co., St. Louis, MO, USA). Cultures were
maintained on plastic at 378C in a 5% CO2 humidified
atmosphere.
MCA3D and PDV cells were co-transfected with an
expression vector for the neomycin resistance gene, pcDNA3
(In Vitrogene, San Diego, CA, USA) and plasmids contain-
ing a full-length Smad4/DPC4 cDNA or a C-terminal
truncated dominant-negative Smad4/DPC4 (1 – 514) construct
(Lagna et al., 1996), under the control of the cytomegalovirus
promoter. The Smad4 plasmids were kindly provided by Dr
Joan Massague´ (Memorial Sloan-Kettering Cancer Center,
New York). Transfections were made in DMEM medium
using lipofectamine reagent (Life Technologies, Gaithersburg,
MD, USA). Cells were selected in complete Ham’s F-12
medium containing 400 mg/ml of G418 (Calbiochem-Nova-
biochem Co) for 2 weeks, and G418-resistant clones isolated
by cloning rings.
Transient co-transfection assays with the 3TP-lux reporter
construct and with a lacZ plasmid to score transfection
eciency, were performed as described previously (Santiba´-
n˜ez et al., 1999).
For TGF-b1 treatments, human recombinant TGF-b1
(Calbiochem-Novabiochem Intl., La Jolla, CA, USA) was
used. The growth factor was added to the cell cultures at a
final concentration of 10 ng/ml.
For cell growth assays, cells were synchronized by leaving
them at confluence for 24 h. Equivalent numbers of
synchronously growing cells were seeded in 20-cm2 plates in
standard medium. After 18 h, fresh medium with or without
TGF-b1 was added, and the total number of cells determined
48 h later in a Coulter counter.
PD098059 was obtained from Calbiochem-Navabiochem
Intl. and added to the cell cultures 20 min prior to
stimulation with TGF-b1, at the indicated concentrations, in
serum-free medium. Then, cells were washed and grown in
fresh medium, plus or minus serum, in the presence or
absence of TGF-b1.
Infection of MCA3D transfectant clones with the Harvey
murine sarcoma virus (carrying the viral H-Ras oncogene)
was achieved with high-titer viral supernatants obtained by
growing C2-MDRas cells to confluence, as described by
Missero et al. (1991).
Wound healing assay
Cellular motility was assayed by an in vitro wound model.
Subconfluent cell monolayers were gently scratched with a tip
to produce a ‘wound’. Then, cultures were allowed to grow
for 24 h in standard medium with or without TGF-b1.
Synthesis of peptide P41 – 54 (VSYKYFSRIRRCSC), com-
Figure 9 Histological appearance of tumours induced by PDV cell transfectants. PC clones gave rise to well dierentiated
squamous cell carcinomas as that showed for PC2. PdnS clones produced poorly dierentiated tumours as the one showed for
PdnS8, in which squamous dierentiated components were absent or present only in minority regions. Bar, 30 mm
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prising amino acid residues 41 – 54 of the EGF-like domain
of mouse uPA, and unrelated peptides derived from gelatin
by limited trypsin degradation, used as a control, are
described elsewhere (Santiba´n˜ez et al., 1999). Peptides were
added to the culture media, at 150 mg/ml, at the same time as
TGF-b1.
Immunofluorescence analysis
Immunofluorescence stainings for Smad2,3 and Erk1,2
proteins were performed by conventional procedures, in cells
fixed and permeabilized in cold methanol, with polyclonal
antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA): E-20, specific for Smad2 and Smad3, and K-23, which
recognizes both Erk1 and Erk2 isoforms. Antibodies were
used at 1 : 50 dilution in PBS containing 2% BSA.
Rhodamine-conjugated anti-goat and anti-rabbit IgG (Jack-
son ImmunoResearch Lab., West Grove, PA, USA),
respectively, were used as secondary antibodies. Dierent
fields containing 30 – 60 cells were photographed, and the
percentage of cells with Smad2,3 or Erk1,2 accumulated in
the nucleus determined counting 10 distinct fields from
triplicates corresponding to each experimental situation.
Western blot analysis
Cells were lysed in RIPA buer (50 mM NaCl, 1% NP-40,
0,5% sodium deoxycholate, 0,1% SDS, 50 mM Tris-HCl,
pH 7.5) and a cocktail of proteinase inhibitors (2 mg/ml
aprotinin, 2 mg/ml leupeptin and 1 mM phenylmethylsulpho-
nyl fluoride). For phospho-Erk determinations, phosphatase
inhibitors: 1 mM sodium orthovanadate, 50 mM sodium
fluoride, 10 mM sodium pyrophosphate and 2 mM hydrogen
peroxide, were added to the lysis buer. For Ras protein
determinations a lysis buer containing 100 mM NaCl, 5 mM
CaCl2, 5 mM MgCl2, 2% SDS, 50 mM Tris HCl, pH 7.4, and
proteinase inhibitors was used. Proteins (20 or 30 mg/lane)
were resolved by SDS–PAGE and transferred to Immobilon
P membranes (Millipore Corp., Bedford, MA, USA). Ras
proteins were detected by a pan-Ras monoclonal antibody
(Ab-3, Oncogene Science Inc., Uniondale, NY, USA). For
p21Cip1 and phospho-Erk1,2 protein determinations, a poly-
clonal antibody (C-20) and a monoclonal antibody (E-4),
respectively, both from Santa Cruz Biothechnology Inc., were
used as primary antibodies, followed by exposure to
peroxidase-conjugated secondary antibodies (Amersham Intl.
Plc. Amersham Bucks, UK), and developed using the
enhanced chemoluminescent system (ECL, Amersham Corp.,
Arlington Heights, FL, USA). The bands detected in the
Western blots were quantified by scanning and digitalization
of the X-ray films.
Measurement of Ras activation and zymographic assays
The capacity of Ras-GTP to bind the Ras-binding domain of
Raf-1 (RBD) was used to analyse the level of active Ras in
the cells (de Rooij and Bos, 1997). Briefly, cleared cell lysates
(0.7 – 1.1 mg of total protein) were incubated with 30 mg of
the fusion protein GST-RBD bound to glutathione-Sephar-
ose beads. Beads were washed and bound proteins solubilized
in Laemmli buer and resolved in SDS –PAGE. Proteins
were then immunoblotted as described above, and precipi-
tated Ras-GTP detected using a pan-Ras monoclonal anti-
body. The level of Ras protein expression was determined in
the cell lysates by Western immunoblotting using the same
antibody.
uPA-secreted activity of cell cultures was determined by
caseinolytic zymography, as previously reported (Santiba´n˜ez
et al., 1999). Aliquots (20 – 30 ml) of conditioned serum-free
medium, normalized for the same amount of protein (0.5 mg/
ml in PDV experiments, and 2.5 mg/ml in MCA3D experi-
ments), were first subjected to SDS –PAGE under nonredu-
cing conditions, and then to zymography on agarose gels
containing casein and plasminogen.
Tumorigenicity assays and histopathology
Suspensions of 1 – 26106 cells were injected intradermaly into
the flanks of 8 – 10-week-old Swiss athymic nude mice
(CRIFFA, Barcelona, Spain). Animals were observed for
tumour formation, and the size of tumours (in cm2)
calculated from caliper measurements of two orthogonal
diameters at dierent times. Histological typing of all
developed tumours was performed on formalin-fixed and
paran-embedded sections by staining with hematoxylin and
eosin.
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